|
NDSRI growth with respect to age
|
|
0
|
23
|
January 19, 2026
|
|
Sufentanil Nitroso impurity standard
|
|
1
|
83
|
January 15, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
2
|
357
|
January 7, 2026
|
|
N-nitrosamides, N-nitrosoureas, Nnitrosoguanidines
|
|
7
|
471
|
December 30, 2025
|
|
Establishing Best Practice for N- Nitrosamine Read-Across and Surrogate Selection
|
|
0
|
145
|
December 22, 2025
|
|
N-Nitroso Abemaciclib
|
|
13
|
559
|
December 22, 2025
|
|
N-nitroso-rivaroxaban amide
|
|
6
|
1771
|
December 17, 2025
|
|
N-Nitroso vonoprazan
|
|
1
|
223
|
December 15, 2025
|
|
Nitrosamines in macrocyclic antibiotics
|
|
2
|
206
|
December 10, 2025
|
|
Issue Regarding Purchase of N-Nitroso N-Desmethyl Rosuvastatin Reference Standard
|
|
5
|
225
|
December 10, 2025
|
|
Issue with Area Drop During N-Nitroso Dorzolamide Method Setup
|
|
3
|
182
|
December 10, 2025
|
|
NDSRI in Pyrathiazine theocolate
|
|
3
|
286
|
December 5, 2025
|
|
WHO Updates on Nitrosamine Impurities
|
|
3
|
601
|
December 3, 2025
|
|
FDA Approves Reformulated Ranitidine - Nitrosamine Impurities - NDMA
|
|
3
|
405
|
November 27, 2025
|
|
𝗡-𝗡𝗶𝘁𝗿𝗼𝘀𝗮𝗺𝗶𝗻𝗲 𝗙𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗗𝗿𝘂𝗴 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀: 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗮 𝗕𝗶𝗮𝘀𝗲𝗱, 𝗖𝗼𝗻𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝘃𝗲, 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝘃𝗲 𝗠𝗼𝗱𝗲𝗹
|
|
1
|
309
|
November 26, 2025
|
|
N-Nitrosamine Formation in Pharmaceutical Drug Products: Development and Validation of a Biased, Conservative, Predictive Model-Pub
|
|
4
|
426
|
November 24, 2025
|
|
In Vitro Metabolism Study of NDSRIs
|
|
3
|
264
|
November 20, 2025
|
|
Studies addressing potential bioactivation and genotoxicity liabilities of the N-nitroso derivative of the antidepressant paroxetine-Pub
|
|
0
|
104
|
November 18, 2025
|
|
N-Nitroso Sertraline
|
|
9
|
882
|
October 23, 2025
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
10
|
718
|
September 22, 2025
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
18
|
5063
|
September 20, 2025
|
|
Nitrosamines risk in cleaning validation approach
|
|
11
|
349
|
September 4, 2025
|
|
Ask for help with limit for Nitroso-olaparib
|
|
2
|
209
|
September 4, 2025
|
|
👨💻 Quantitative Analysis of NDMA, N-Nitroso-l-ephedrine and N-Nitroso-pseudoephedrine in Pseudoephedrine Hydrochloride by HPLC-Tandem MS
|
|
2
|
476
|
August 28, 2025
|
|
Three-Pronged Approach (Active Pharmaceutical Ingredients, Excipients, and NOx-Free Air) Successfully Suppressed the Formation of Nitroso-atomoxetine to 0.097 ppm
|
|
0
|
441
|
August 24, 2025
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
20
|
4416
|
August 18, 2025
|
|
Testing of N-nitroso-cinacalcet
|
|
6
|
876
|
May 25, 2025
|
|
Primary amines in formation of nitrosamine
|
|
6
|
906
|
August 13, 2025
|
|
Nitrosamine Risk Mitigation Calculator (by DFE Pharma)
|
|
1
|
1087
|
August 11, 2025
|
|
🇺🇸 FDA - Fiscal Year 2024 Generic Drug Science and Research Initatives Public Workshop
|
|
21
|
2129
|
August 7, 2025
|